Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will A CV Warning On Meridia Alter FDA Views On Obesity Drugs?

This article was originally published in The Pink Sheet Daily

Executive Summary

The diet pill was not approved or recommended for use in about 90 percent of patients in the trial that triggers the warning, Abbott says.
Advertisement

Related Content

Eisai's High Dose Aricept Beats Expectations, But Lack Of Solutions Plague Mid-term Forecast
Vivus' Qnexa Gets "Complete Response" Letter From FDA
Vivus' Qnexa Gets "Complete Response" Letter From FDA
Can CV Monitoring Warnings Or REMS Restrictions Save Abbott's Meridia?
Can CV Monitoring Warnings Or REMS Restrictions Save Abbott's Meridia?
Market Snapshot: Obesity Space Is ‘Not For The Faint of Heart’
Market Snapshot: Obesity Space Is ‘Not For The Faint of Heart’
FDA Will Soon Finalize Obesity Guidance, May Tackle CV Safety Separately
Sanofi Withdraws Zimulti NDA For Weight Loss

Topics

Advertisement
UsernamePublicRestriction

Register

PS068797

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel